Rallybio Corp.(RLYB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RLYB Rallybio Corp.

Closed New Year's Day 12-31 16:00:00 EST

0.9600

+0.0310

+3.34%

盘后0.9289

-0.0311-3.24%

19:46 EST

High0.9875	Low0.9000	Vol110.03K
Open0.9000	D1 Closing0.9290	Amplitude9.42%
Mkt Cap39.83M	Tradable Cap18.22M	Total Shares41.49M
T/O104.08K	T/O Rate0.58%	Tradable Shares18.98M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"RLYB","market":"US","secType":"STK","nameCN":"Rallybio Corp.","latestPrice":0.96,"timestamp":1735678800000,"preClose":0.929,"halted":0,"volume":110028,"hourTrading":{"tag":"盘后","latestPrice":0.9289,"preClose":0.96,"latestTime":"19:46 EST","volume":1013,"amount":953.7599,"timestamp":1735692370403},"delay":0,"floatShares":18975305,"shares":41487586,"eps":-1.574425,"marketStatus":"Closed New Year's Day","change":0.031,"latestTime":"12-31 16:00:00 EST","open":0.9,"high":0.9875,"low":0.9,"amount":104083.6932888,"amplitude":0.094187,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.574425,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1735808400000},"marketStatusCode":7,"adr":0,"listingDate":1627531200000,"exchange":"NASDAQ","adjPreClose":0.929,"preHourTrading":{"tag":"盘前","latestPrice":0.929,"preClose":0.929,"latestTime":"09:21 EST","volume":45,"amount":41.8041,"timestamp":1735654896335},"postHourTrading":{"tag":"盘后","latestPrice":0.9289,"preClose":0.96,"latestTime":"19:46 EST","volume":1013,"amount":953.7599,"timestamp":1735692370403},"volumeRatio":0.8062100475671227},"requestUrl":"/m/hq/s/RLYB","defaultTab":"news","newsList":[{"id":"2490479330","title":"Promising Preclinical Data and Clinical Advancements Justify Buy Rating for Rallybio","url":"https://stock-news.laohu8.com/highlight/detail?id=2490479330","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490479330?lang=en_us&edition=fundamental","pubTime":"2024-12-11 03:05","pubTimestamp":1733857512,"startTime":"0","endTime":"0","summary":"In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Rallybio (RLYB – Research Report), with a price target...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-preclinical-data-and-clinical-advancements-justify-buy-rating-for-rallybio?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-preclinical-data-and-clinical-advancements-justify-buy-rating-for-rallybio?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RLYB"],"gpt_icon":0},{"id":"2490013536","title":"Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490013536","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490013536?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:00","pubTimestamp":1733835600,"startTime":"0","endTime":"0","summary":"NEW HAVEN, Conn., December 10, 2024----Rallybio Corporation , a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of two posters highlighting promising preclinical data for pipeline candidates RLYB212 and RLYB332 at the 66th American Society of Hematology  Annual Meeting and Exposition, taking place December 7–10, 2024 in San Diego, California.In a poster titled \"Prophylactic Administration of HPA-1a–Specific Antibody RLYB212 Safely Prevents Fetal/Neonatal Alloimmune Thrombocytopenia Due to HPA-1a Incompatibility in Pregnant Mice,\" preclinical data was presented demonstrating that prophylactic administration of RLYB212 to pregnant mice at doses of 1.01 or 5.05 g/kg prevented maternal alloimmunization. Further, pups born to RLYB212-treated, but not untreated, pregnant mice had normal platelet counts, demonstrating the ability of RLYB212 to prevent fetal and neon","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ERnMbiWAy4mpHEhpi6LTCA--~B/aD0yNDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/93c5bc7c78f3dd6334bf5afc3752d0bb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ERnMbiWAy4mpHEhpi6LTCA--~B/aD0yNDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/93c5bc7c78f3dd6334bf5afc3752d0bb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rallybio-announces-promising-rlyb212-rlyb332-130000963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","RLYB","TSAT","LU1169589451.USD","LU1169590202.USD","PHH","BK4089","AFG","BK4023","BK4117","PD","ASH","BK4139","WRD","BK4109","LU2463526074.USD","BK4107"],"gpt_icon":0},{"id":"2489463540","title":"TD Cowen Keeps Their Buy Rating on Rallybio (RLYB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489463540","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489463540?lang=en_us&edition=fundamental","pubTime":"2024-12-05 23:17","pubTimestamp":1733411858,"startTime":"0","endTime":"0","summary":"In a report released on December 3, Ritu Baral from TD Cowen maintained a Buy rating on Rallybio (RLYB – Research Report). The company’s shares ope...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-rallybio-rlyb?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-rallybio-rlyb?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","TD","RLYB"],"gpt_icon":0},{"id":"2489583430","title":"Rallybio price target lowered to $7 from $8 at JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2489583430","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489583430?lang=en_us&edition=fundamental","pubTime":"2024-12-05 19:48","pubTimestamp":1733399304,"startTime":"0","endTime":"0","summary":"JMP Securities analyst Jonathan Wolleben lowered the firm’s price target on Rallybio (RLYB) to $7 from $8 and keeps an Outperform rating on the sha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rallybio-price-target-lowered-to-7-from-8-at-jmp-securities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rallybio-price-target-lowered-to-7-from-8-at-jmp-securities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JMP","RLYB"],"gpt_icon":0},{"id":"2488163913","title":"Rallybio Price Target Maintained With a $5.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2488163913","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488163913?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:36","pubTimestamp":1733225760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RLYB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2024 06:36 ET (11:36 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLYB"],"gpt_icon":0},{"id":"2488918940","title":"Rallybio’s RLYB116: Promising Developments and Buy Rating Driven by Enhanced Manufacturing and Potential in Phase 1 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2488918940","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488918940?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:15","pubTimestamp":1733224532,"startTime":"0","endTime":"0","summary":"Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Rallybio (RLYB – Research Report). The associated price target remai...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rallybios-rlyb116-promising-developments-and-buy-rating-driven-by-enhanced-manufacturing-and-potential-in-phase-1-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rallybios-rlyb116-promising-developments-and-buy-rating-driven-by-enhanced-manufacturing-and-potential-in-phase-1-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RLYB"],"gpt_icon":0},{"id":"2488855950","title":"Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2488855950","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488855950?lang=en_us&edition=fundamental","pubTime":"2024-12-02 21:00","pubTimestamp":1733144400,"startTime":"0","endTime":"0","summary":"-- New Biomarker Characterization Analyses Indicate RLYB116 Produced Complete and Sustained Complement Inhibition in Previous Phase 1 MAD Study –。-- Manufacturing Process Enhancements Expected to Further Improve RLYB116 Tolerability --. \"Recently completed efforts to better understand the disconnect between the compelling preclinical potency data of RLYB116 and the results of the Phase 1 study indicate that RLYB116 achieved greater complement inhibition in the Phase 1 study than initially reported,\" said Stephen Uden, M.D., Chief Executive Officer of Rallybio. \"This, together with successful manufacturing process enhancements to further improve the tolerability profile, uniquely positions RLYB116 as a potentially best-in-class C5 inhibitor that can meet patient demand for a once-weekly, small volume, subcutaneous, self-administered therapeutic. We look forward to bringing RLYB116 into a confirmatory clinical PK/PD study in the second quarter of 2025 and expect RLYB116 to demonstrate co","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fKE11IZMSm_lIJxjLeEcqA--~B/aD0yNDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e455e1e2e8d13c9b6396185fa6728baa","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fKE11IZMSm_lIJxjLeEcqA--~B/aD0yNDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e455e1e2e8d13c9b6396185fa6728baa"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rallybio-initiate-rlyb116-confirmatory-clinical-130000958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4539","LU1169589451.USD","WRD","LU1169590202.USD","PD","RLYB","BK4139","BK4218","BK4181","BK4023"],"gpt_icon":0},{"id":"2486878057","title":"Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women","url":"https://stock-news.laohu8.com/highlight/detail?id=2486878057","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486878057?lang=en_us&edition=fundamental","pubTime":"2024-11-27 21:00","pubTimestamp":1732712400,"startTime":"0","endTime":"0","summary":"— Dosing Regimen to be Evaluated in Recently Initiated RLYB212 Phase 2 Clinical Trial —。NEW HAVEN, Conn., November 27, 2024----Rallybio Corporation , a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the publication of a manuscript titled, \"Informing Pregnancy Dose via Target-Mediated Drug Disposition Modeling and Simulations for a Recombinant Human Monoclonal Antibody,\" in a special pregnancy themed issue of Clinical Pharmacology and Therapeutics: Pharmacometrics & Systems Pharmacology.Rallybio is developing RLYB212, a novel human monoclonal anti-HPA-1a antibody, to prevent alloimmunization in pregnant women and thereby eliminate the risk of FNAIT and its potentially devastating consequences in their fetuses and newborns. Rallybio recently announced the initiation of screening in its Phase 2 dose confirmation trial in pregnant women at higher risk for HPA-1a alloimmunization","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CEqqLVz1mck10.pYlSVLEw--~B/aD0yNDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5dfcd513ec20432446ef3836711b3472","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CEqqLVz1mck10.pYlSVLEw--~B/aD0yNDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5dfcd513ec20432446ef3836711b3472"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rallybio-announces-publication-target-mediated-130000249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["WRD","BK4139","BK4539","RLYB"],"gpt_icon":0},{"id":"2486070018","title":"Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486070018","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486070018?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:00","pubTimestamp":1732626000,"startTime":"0","endTime":"0","summary":"NEW HAVEN, Conn., November 26, 2024----Rallybio Corporation , a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET in Coral Gables, FL.A live webcast of the fireside chat will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation.Investor Contacts Samantha TracyRallybio Corporation 47-RALLY investors@rallybio.com Kevin LuiPrecision AQ 698-8691Kevin.Lui@precisionaq.com Media Victoria ReynoldsMission North 579-2134rallybio@missionnorth.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ixgRjvcu8i7d67fRjN2cpg--~B/aD0yNDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b59584facfc9c5d078a3b9dcf8ceeed2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ixgRjvcu8i7d67fRjN2cpg--~B/aD0yNDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b59584facfc9c5d078a3b9dcf8ceeed2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rallybio-present-2024-evercore-isi-130000476.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["WRD","RLYB","BK4139","BK4539"],"gpt_icon":0},{"id":"2486089920","title":"BRIEF-Rallybio To Provide Update On Rlyb116 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2486089920","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486089920?lang=en_us&edition=fundamental","pubTime":"2024-11-25 21:12","pubTimestamp":1732540344,"startTime":"0","endTime":"0","summary":"Nov 25 (Reuters) - Rallybio Corp   :   * RALLYBIO TO PROVIDE UPDATE ON RLYB116 PROGRAM, AN INNOVATIVE SUBCUTANEOUSLY INJECTED C5 INHIBITORSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2357305700.SGD","RLYB","BK4585","BK4539","LU0348723411.USD","LU1720051017.SGD","BK4588","LU1978683503.SGD","BK4512","LU1854104046.USD","IE00BD6J9T35.USD","LU0724618433.USD","LU1861215975.USD","LU1861219969.SGD","LU1861220033.SGD","LU1854103824.USD","LU1861214812.USD","LU1548497426.USD","LU2360107325.USD","BK4141","LU2298322129.HKD","LU1720051108.HKD","IE00BZ199S13.USD","LU0124384867.USD"],"gpt_icon":0},{"id":"2486086794","title":"Rallybio to Provide Update on Rlyb116 Program, an Innovative Subcutaneously Injected C5 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2486086794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486086794?lang=en_us&edition=fundamental","pubTime":"2024-11-25 21:00","pubTimestamp":1732539601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nTUA203YQ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLYB","BK4539","BK4139"],"gpt_icon":0},{"id":"2486908132","title":"Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2486908132","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486908132?lang=en_us&edition=fundamental","pubTime":"2024-11-25 21:00","pubTimestamp":1732539600,"startTime":"0","endTime":"0","summary":"-- Webcast to be held on Monday, December 2, 2024 at 8:30 AM Eastern Time --. NEW HAVEN, Conn., November 25, 2024----Rallybio Corporation , a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the Company will host a webcast to provide a program update on RLYB116, its innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of patients with complement-mediated diseases. The webcast will take place on Monday, December 2 at 8:30 AM Eastern Time and will review recent manufacturing process enhancements, biomarker characterization analyses, and the Company’s future plans for the program.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qSNTUyIWQ7SYDsDLdsddPA--~B/aD0yNDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a037434d8bbbc63998a56d8255c17949","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qSNTUyIWQ7SYDsDLdsddPA--~B/aD0yNDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a037434d8bbbc63998a56d8255c17949"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rallybio-rlyb116-program-innovative-subcutaneously-130000977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","RLYB","BK4139"],"gpt_icon":1},{"id":"2485252423","title":"Rallybio Price Target Maintained With a $5.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2485252423","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485252423?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:39","pubTimestamp":1732279140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RLYB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 22, 2024 07:39 ET (12:39 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLYB"],"gpt_icon":0},{"id":"2485495819","title":"BRIEF-Rallybio Announces Initiation Of Phase 2 Clinical Trial Of RLYB212","url":"https://stock-news.laohu8.com/highlight/detail?id=2485495819","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485495819?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:06","pubTimestamp":1732194393,"startTime":"0","endTime":"0","summary":"BRIEF-Rallybio Announces Initiation Of Phase 2 Clinical Trial Of RLYB212Nov 21 (Reuters) - Rallybio Corp RLYB.O:RALLYBIO ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL OF RLYB212RALLYBIO CORP - PHASE ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA8JQ0PR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLYB","BK4139","BK4539"],"gpt_icon":0},{"id":"2485493657","title":"Rallybio Announces Initiation of Phase 2 Clinical Trial of Rlyb212","url":"https://stock-news.laohu8.com/highlight/detail?id=2485493657","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485493657?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:00","pubTimestamp":1732194000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA8JQ0PR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","RLYB"],"gpt_icon":0},{"id":"2485493438","title":"Rallybio Corp - Trial to Enroll Participants in Belgium, Netherlands, Norway, Sweden, UK","url":"https://stock-news.laohu8.com/highlight/detail?id=2485493438","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485493438?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:00","pubTimestamp":1732194000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA8JQ0PR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLYB","BK4539","BK4139"],"gpt_icon":0},{"id":"2485493129","title":"Rallybio Corp - Phase 2 Trial to Assess Pk and Safety of Rlyb212","url":"https://stock-news.laohu8.com/highlight/detail?id=2485493129","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485493129?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:00","pubTimestamp":1732194000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA8JQ0PR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","RLYB"],"gpt_icon":0},{"id":"2485349905","title":"Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212","url":"https://stock-news.laohu8.com/highlight/detail?id=2485349905","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485349905?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:00","pubTimestamp":1732194000,"startTime":"0","endTime":"0","summary":"— Screening is Now Underway to Identify Pregnant Women at Higher Risk for HPA-1a Alloimmunization and FNAIT —。NEW HAVEN, Conn., November 21, 2024----Rallybio Corporation , a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of its Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia . Screening is now underway to identify the first  pregnant woman for enrollment in the Phase 2 trial.About FNAITFetal and Neonatal Alloimmune Thrombocytopenia  is a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. FNAIT can arise during pregnancy due to an immune incompatibility betw","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8KUxvh_GV_N2ibqHoWeBvw--~B/aD0yNDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7d5f202f4482e9b27f466579db9be517","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8KUxvh_GV_N2ibqHoWeBvw--~B/aD0yNDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7d5f202f4482e9b27f466579db9be517"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rallybio-announces-initiation-phase-2-130000979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4181","BK4139","BK4539","RLYB","PK"],"gpt_icon":1},{"id":"2481178461","title":"Rallybio price target lowered to $5 from $6 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2481178461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481178461?lang=en_us&edition=fundamental","pubTime":"2024-11-08 19:30","pubTimestamp":1731065457,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Rallybio (RLYB) to $5 from $6 and keeps a Buy rating on the shares following the Q3 report. Publ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rallybio-price-target-lowered-to-5-from-6-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rallybio-price-target-lowered-to-5-from-6-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RLYB"],"gpt_icon":0},{"id":"2481783521","title":"Rallybio Corporation : H.c. Wainwright Cuts Target Price to $5 From $6","url":"https://stock-news.laohu8.com/highlight/detail?id=2481783521","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481783521?lang=en_us&edition=fundamental","pubTime":"2024-11-08 19:27","pubTimestamp":1731065239,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nAZN2LBYW9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RLYB","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rallybio.com","stockEarnings":[{"period":"1week","weight":0.1201},{"period":"1month","weight":-0.1795},{"period":"3month","weight":-0.1193},{"period":"6month","weight":-0.25},{"period":"1year","weight":-0.5983},{"period":"ytd","weight":-0.5983}],"compareEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":-0.0273},{"period":"3month","weight":0.0303},{"period":"6month","weight":0.0628},{"period":"1year","weight":0.233},{"period":"ytd","weight":0.233}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.034732},{"month":2,"riseRate":0.666667,"avgChangeRate":0.253337},{"month":3,"riseRate":0,"avgChangeRate":-0.281213},{"month":4,"riseRate":0.666667,"avgChangeRate":0.136243},{"month":5,"riseRate":0.666667,"avgChangeRate":0.18788},{"month":6,"riseRate":0,"avgChangeRate":-0.283985},{"month":7,"riseRate":1,"avgChangeRate":0.109871},{"month":8,"riseRate":0.25,"avgChangeRate":-0.081287},{"month":9,"riseRate":0.75,"avgChangeRate":0.074309},{"month":10,"riseRate":0.5,"avgChangeRate":-0.049333},{"month":11,"riseRate":0.25,"avgChangeRate":-0.27145},{"month":12,"riseRate":0.5,"avgChangeRate":-0.011574}],"exchange":"NASDAQ","name":"Rallybio Corp.","nameEN":"Rallybio Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rallybio Corp.(RLYB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rallybio Corp.(RLYB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rallybio Corp.,RLYB,Rallybio Corp.股票,Rallybio Corp.股票老虎,Rallybio Corp.股票老虎国际,Rallybio Corp.行情,Rallybio Corp.股票行情,Rallybio Corp.股价,Rallybio Corp.股市,Rallybio Corp.股票价格,Rallybio Corp.股票交易,Rallybio Corp.股票购买,Rallybio Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rallybio Corp.(RLYB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rallybio Corp.(RLYB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction